Immune evolution in pre-invasive lung adenocarcinoma

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-05-08 DOI:10.1016/j.ccell.2025.04.005

Adithya Balasubramanian, Marie-Liesse Asselin-Labat

引用次数: 0

Abstract

The mechanisms governing the progression of precursor lesions to invasive lung adenocarcinoma (LUAD) remain poorly understood. In this issue of Cancer Cell, Zhu et al. map the dynamic immune changes associated with this progression using high-resolution spatial mapping. Their identification of TIM-3 as a potential target may shift strategies for LUAD immunoprevention.

查看原文本刊更多论文

侵袭前肺腺癌的免疫进化

控制浸润性肺腺癌（LUAD）前驱病变进展的机制仍然知之甚少。在这一期的《癌细胞》杂志上，Zhu等人使用高分辨率空间制图绘制了与这种进展相关的动态免疫变化。他们对TIM-3作为潜在靶点的识别可能会改变LUAD免疫预防策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.